Yvonne Greenstreet

Yvonne Greenstreet is a prominent figure in the field of pharmacology and healthcare industry. She is known for her significant contributions to the development and commercialization of innovative medicines that have had a profound impact on patients' lives.

Early Life and Education[edit | edit source]

Yvonne Greenstreet was born and raised in the United Kingdom. She pursued her undergraduate studies in Medicine at the University of Leeds, where she graduated with honors. She later earned an MBA from INSEAD, one of the world's leading and largest graduate business schools.

Career[edit | edit source]

Greenstreet has over 25 years of experience in the healthcare industry, with a focus on drug development and strategic planning. She began her career at Pfizer, where she held several senior leadership roles, including Senior Vice President and Head of Medicines Development Group for the company's Specialty Care Business.

In 2011, Greenstreet joined GlaxoSmithKline (GSK) as Senior Vice President and Head of Global Medicines Development and Chief Medical Officer. During her tenure at GSK, she led the development of a robust pipeline of innovative medicines and played a key role in the company's strategic business decisions.

In 2016, Greenstreet joined Alnylam Pharmaceuticals as the Chief Operating Officer. At Alnylam, she has been instrumental in the development and commercialization of RNAi therapeutics, a revolutionary approach to treating diseases.

Recognition[edit | edit source]

Greenstreet's contributions to the field of pharmacology have been widely recognized. She was named one of the Top 50 Most Powerful Women in Corporate America by Black Enterprise in 2015 and has been listed in the PharmaVOICE 100, a list of the most inspiring people in the life sciences industry.